Australia's largest stock trading and investment forum Australia's #1 stock forum

BNO

0.00%

1.0¢ bionomics limited

Ann: Preliminary Final Report FY2021 App 4E and Announcement, page-11

First 11 Last

Share
Profile

Follow
vivRookie

6,241 Posts.

566

13/09/21

14:42

Post #: 56022702
Share

Originally posted by JamesTas: ↑

Yes, this stock seems to starve on lack of news, making a few nervous.

MODULATE results are a little overdue but remember they were originally scheduled for 2023 - so still ok in my book, although they do need to address this very soon with an update as the delay is a poor look and impacts confidence.

Bionomics Ltd (ASX:BNO) (OTCMKTS:BNOEF) (FRA:B1N) has completed the MODULATE clinical trial, an experimental phase 2 trial of its drug candidate BNC105 in combination with Bristol Myers Squibb’s (NYSE:BMY) nivolumab, in patients with metastatic colorectal cancer.The trial sponsor, the Australasian Gastro-Intestinal Trials Group (AGITG), is expecting that results will be ready in the second quarter of 2021, which is ahead of the previously announced timeline for topline data of early 2023.ATTUNE - I can't find anything more on since the July announcement.
It's a 12 week trial with topline results expected in 2023.
Have to admit that it does seem a long time away without any updates on when it is likely start - or if it has started?
Some progress updates would be useful and help avoid the shareholder angst.

Science seems to make sense to me and so I'm sticking around a bit longer.

Expand

Just got to accept Captain Snooze is at his usual lack of regular communication.. but this keeps bouncing up..
hands up those who managed to snatch it at 16.5? we get some nice buying opportunities

BNO Price at posting: 17.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

There are more pages in this discussion • 5 more messages in this thread...

First 11 Last

Add BNO (ASX) to my watchlist

Ann: Preliminary Final Report FY2021 App 4E and Announcement, page-11

Top Stories

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Featured News